Timing note: McKesson is scheduled to report after the close today, Wednesday, August 5, 2026, with its earnings call at 4:30 p.m. ET. This is therefore a same-day preview, not a preview for tomorrow. The report covers the quarter ended June 30, 2026.
McKesson enters fiscal 2027 with real operating momentum: specialty distribution, oncology/multispecialty services, biopharma access solutions, and an unusually large buyback program should support double-digit adjusted EPS growth. The central question is not whether MCK can grow, but whether its first-quarter results and commentary validate the $43.80–$44.60 fiscal-year adjusted EPS framework—especially given a stock that closed at $830.47 on August 4, roughly 10% above its May 7 close and only about 6.6% below its July 28 high.
My base case is that MCK should deliver a solid operating quarter, but the stock reaction will depend more on:
1. confidence in full-year guidance,
2. the pace of North American Pharmaceutical profit growth amid branded-price pressure and GLP-1 variability, and
3. tangible progress on the Medical-Surgical separation and associated capital return.
At its May fiscal-year-end report, MCK initiated FY27 adjusted EPS guidance of $43.80–$44.60, representing approximately 12%–14% growth from FY26 adjusted EPS of $39.11. The company characterized the implied underlying growth as 14%–16% when excluding prior-year Norway earnings and a gain on an Oncology & Multispecialty investment sale.
This will be the principal read-through:
At the August 4 closing price, the midpoint of FY27 guidance implies roughly 18.8x adjusted EPS. That valuation leaves less room for a merely adequate quarter; investors likely need confirmation that earnings can land toward the middle-to-upper portion of the guide.
North American Pharmaceutical remains the core earnings engine. For FY27, management guided to:
| FY27 outlook | Revenue growth | Adjusted operating-profit growth |
|---|---|---|
| North American Pharmaceutical | 4%–8% | 5.5%–9.5% |
The revenue outlook is deliberately more restrained than the underlying business momentum because McKesson is lapping a large customer onboarding, Rite Aid-related revenue, and branded-drug manufacturer price reductions. In fiscal Q4, branded-price changes reduced North American Pharmaceutical revenue growth by roughly 3 percentage points, while management said the impact did not affect operating profit.
What to watch:
The key investor takeaway: a revenue “miss” driven by price or customer-lapping effects should be less concerning if segment operating profit remains on track. Conversely, weak profit growth would challenge the premise that specialty mix and automation can offset those revenue headwinds.
This is MCK’s highest-priority growth platform. FY27 guidance calls for:
| FY27 outlook | Revenue growth | Adjusted operating-profit growth |
|---|---|---|
| Oncology & Multispecialty | 14.5%–18.5% | 13.5%–17.5% |
The segment delivered 35% revenue growth and 53% adjusted operating-profit growth in fiscal Q4, aided by contributions from PRISM Vision and Core Ventures. Excluding acquisitions, management said organic operating-profit growth was about 13%.
For Q1, investors should focus on whether growth remains broad-based after the acquisition anniversary:
The risk is not a sudden demand collapse; it is that organic growth moderates faster than expected as acquisition comparisons become less favorable. A clean quarter with maintained mid-teens segment expectations would reinforce the segment’s role as MCK’s multi-year profit-growth engine.
FY27 guidance for Prescription Technology Solutions is 2.5%–6.5% revenue growth but 11%–15% adjusted operating-profit growth. That spread is intentional: third-party logistics represents about 55% of segment revenue and can fluctuate materially based on launches, program timing, supply dynamics, and product transitions. Access and affordability solutions—particularly for complex specialty therapies and GLP-1s—are the more meaningful profit driver.
Investors should prefer:
over simply strong quarterly revenue growth.
The pending Medical-Surgical separation is an important strategic and financial catalyst. MCK previously announced:
The capital structure is therefore becoming more concrete. Management’s FY27 plan included approximately $5 billion of share repurchases and a full-year diluted share count of 116 million–118 million, versus 124.1 million in FY26. The buyback is a meaningful component of the EPS algorithm.
Questions for the call:
| Metric | Fiscal Q1 2026 actual | Fiscal Q4 2026 actual | FY27 guidance / context |
|---|---|---|---|
| Revenue | $97.8B | $96.3B | FY27 company revenue growth: 5%–9% |
| Adjusted EPS | $8.26 | $11.69 | FY27: $43.80–$44.60 |
| North American Pharmaceutical adj. op profit | $950M* | $980M | Growth: 5.5%–9.5% |
| Oncology & Multispecialty adj. op profit | Reported within prior segment structure | $385M | Growth: 13.5%–17.5% |
| Prescription Technology Solutions adj. op profit | $269M | $322M | Growth: 11%–15% |
| Free cash flow | $(1.1)B | $3.2B | FY27: $4.5B–$4.9B |
*Fiscal Q1 2026 used the prior U.S. Pharmaceutical segment presentation, before MCK’s subsequent reporting-structure changes.
The year-ago quarter’s $8.26 adjusted EPS is a useful reference, but it is not a clean run-rate indicator. Fiscal Q1 tends to be MCK’s seasonally lower earnings quarter, and year-over-year comparisons are affected by portfolio changes, repurchases, changing interest expense, noncontrolling interests, and tax timing. Management has said FY27 EPS cadence should be broadly similar to FY26 on a first-half versus second-half basis, while warning that quarter-to-quarter results can vary.
MCK needs to demonstrate that its FY27 guide is intact through operational performance, not just buybacks. The most constructive report would pair stable North American Pharmaceutical margins with continued strong Oncology & Multispecialty growth, double-digit Prescription Technology profit growth, and clear Medical-Surgical separation/capital-return progress.
The main nuance for investors is that revenue can be noisy—especially from branded-price changes, GLP-1 dynamics, and 3PL timing—while operating profit, adjusted EPS guidance, share count, and separation execution are more consequential to the equity story.